TRDA
Entrada Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$6.34-7.98%
Price as of Jul 20, 2026
TRDA financials
Entrada Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $25.4M | $210.8M | $129.0M | $0.00 |
| Cost of revenue | $4.1M | $0.00 | $0.00 | $0.00 |
| Gross profit | $21.3M | $210.8M | $129.0M | $0.00 |
| Operating expenses | $177.3M | $163.8M | $132.2M | $97.2M |
| Operating income | -$156.0M | $47.0M | -$3.2M | -$97.2M |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M |
| EBITDA | -$142.4M | $70.3M | $14.9M | -$90.1M |
| Basic EPS | $-3.47 | $1.76 | $-0.20 | $-2.79 |
| Diluted EPS | $-3.47 | $1.68 | $-0.20 | $-2.79 |
| Balance sheet | ||||
| Cash & equivalents | $90.4M | $101.2M | $67.6M | $45.2M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M |
| Stockholders’ equity | $306.1M | $428.7M | $242.4M | $212.6M |
| Total debt | $50.9M | $59.2M | $68.2M | $25.9M |
| Net debt | -$39.5M | -$42.0M | $628.0K | -$19.2M |
| Cash flow | ||||
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M |
| Capital expenditure | -$1.0M | -$3.2M | -$5.6M | -$2.9M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |